Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRE-2: Bococizumab for cardiovascular event reduction
NCT01975389Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in cardiovascular disease (CVD) and hypercholesterolemia comparing Bococizumab with Placebo (2 arms). Primary endpoint: First Occurrence of Major Cardiovascular (CV) Event up to 3.4 years. Started Oct 2013; status: terminated.
02
Drugs
bococizumab
03
Conditions
cardiovascular disease (CVD)hypercholesterolemia
Beyond the preview
Go deeper on NCT01975389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01975389.